ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PHVS Pharvaris NV

27.81
0.69 (2.54%)
Feb 21 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Pharvaris NV PHVS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.69 2.54% 27.81 19:00:00
Open Price Low Price High Price Close Price Previous Close
27.62 27.02 27.82 27.81 27.12
more quote information »

Recent News

Date Time Source Heading
2/16/202405:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/16/202405:50GLOBEPharvaris Announces Extraordinary Meeting of Shareholders
2/07/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
2/01/202415:46EDGAR2Form 144 - Report of proposed sale of securities
1/26/202405:50GLOBEPharvaris to Present at the WSAAI Annual Meeting 2024
1/22/202406:35DJNPharvaris Says FDA Lifted Clinical Hold on Application for..
1/22/202405:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/22/202405:50GLOBEPharvaris Announces FDA Lifting of the Clinical Hold of..
1/08/202406:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
1/05/202405:50GLOBEPharvaris Provides Business Update and Outlines 2024..
1/02/202415:29EDGAR2Form 144 - Report of proposed sale of securities
12/08/202317:00GLOBEPharvaris Presents Deucrictibant Clinical Data and Analysis..
12/08/202315:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/07/202315:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/06/202315:36EDGAR2Form 144 - Report of proposed sale of securities
12/06/202306:08EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
12/06/202306:02GLOBEPharvaris Announces Pricing of $300 Million Underwritten..
12/06/202305:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/06/202305:50GLOBEPharvaris Announces Positive Top-line Phase 2 Data from the..
11/30/202305:50GLOBEPharvaris to Present at the GA²LEN UCARE Conference 2023
11/15/202305:50GLOBEPharvaris Appoints Stefan Abele, Ph.D., as Chief Technical..
11/09/202310:00GLOBEPharvaris Presents Deucrictibant Clinical Data and..
11/02/202305:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/02/202305:50GLOBEPharvaris Reports Third Quarter 2023 Financial Results and..
10/30/202305:50GLOBEPharvaris To Present at the ACAAI 2023 Annual Scientific..
10/13/202305:50GLOBEPharvaris To Present at the APAAACI 2023 International..
10/04/202306:34GLOBEPharvaris To Present at the CIIC Fall 2023 Conference
9/19/202315:23EDGAR2Form 144 - Report of proposed sale of securities
9/19/202305:50GLOBEPharvaris To Participate in the 2023 Cantor Global..
9/06/202305:51GLOBEPharvaris To Present at the 18th German Allergy Congress
9/06/202305:50GLOBEPharvaris To Participate in the Morgan Stanley 21st Annual..
9/01/202317:02EDGAR2Form 144 - Report of proposed sale of securities
8/24/202315:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
8/23/202305:50GLOBEPharvaris To Present at the 2023 HAEi Regional Conference..
8/16/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
8/09/202318:00EDGAR2Form 144 - Report of proposed sale of securities
8/09/202317:38EDGAR2Form 144 - Report of proposed sale of securities
8/07/202309:16EDGAR2Form F-3 - Registration statement by foreign private issuers
8/07/202305:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
8/07/202305:50GLOBEPharvaris Reports Second Quarter 2023 Financial Results and..
7/21/202309:20GLOBEPharvaris Presents Clinical Data at the 2023 U.S. HAEA..
7/03/202305:50EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
6/26/202306:39DJNPharvaris: FDA Removes Clinical Hold of Deucrictibant for..
6/26/202305:50GLOBEPharvaris Announces FDA Removal of Clinical Hold of..
6/20/202305:50GLOBEPharvaris Announces $70 Million Private Placement Financing
6/10/202317:01GLOBEData of Deucrictibant for the On-Demand Treatment of HAE..
6/01/202305:50GLOBEPharvaris Announces Annual Meeting of Shareholders
5/08/202305:50GLOBEPharvaris Reports First Quarter 2023 Financial Results and..
5/06/202312:00GLOBEDeucrictibant Data Highlighted in Multiple Presentations at..
4/05/202305:51GLOBEPharvaris Reports Fourth Quarter and Full Year 2022..

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com